Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage
Author:
Affiliation:
1. Intercept Pharmaceuticals, Inc San Diego California USA
2. Certara Strategic Consulting Princeton New Jersey USA
3. Department of Medicine University of California San Diego California USA
Publisher
Wiley
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12421
Reference27 articles.
1. Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
2. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid
3. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
4. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
5. 6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. ROS-responsive nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis;Journal of Controlled Release;2024-10
2. Simultaneous determination of Obeticholic acid and its two major metabolites in human plasma after administration of Obeticholic acid tablets using ultra-high performance liquid chromatography tandem mass spectrometry;Journal of Chromatography B;2024-10
3. Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers;Clinical Pharmacology & Therapeutics;2024-08-16
4. Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist;Biomedicine & Pharmacotherapy;2024-04
5. Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH;Liver International;2024-01-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3